VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis

By R. Bibiloni, R. Fedorak, G. Tannock, K. Madsen, P. Gionchetti, M. Campieri, C. Simone, R. Sartor. American Journal of Gastroenterology, 2005

770 citations recorded by the source corpus.

Subfields: Food Science, Genetics, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/a93d9f71983acf5bbfa50843092094d523bcde81

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Food Science

1. R. Sartor
2. Herbert Tilg

In Genetics

1. J. Turner
2. S. Bischoff
3. R. Sartor
4. Herbert Tilg
5. S. Guglielmetti
6. Valentina Taverniti

In Molecular Biology

1. J. Turner
2. S. Bischoff
3. R. Sartor
4. Herbert Tilg
5. V. Khutoryanskiy
6. Dan R. Littman
7. K. Honda
8. P. Cossart

Citations in the corpus

• The immunomodulatory properties of probiotic microorganisms beyond their viability (ghost probiotics: proposal of paraprobiotic concept) (2011, background): “…probiotic cells from VSL#3, a commercial probiotic mixture that contains eight different bacterial strains (four lactobacilli, three bifidobacteria and one Streptococcus thermophilus strain), which was demonstrated to be beneficial in treating inflammatory bowel diseases (Bibiloni et al. 2005).”
• Intestinal permeability – a new target for disease prevention and therapy (2014, background): “For example, VSL#3 seems to be effective not only in pouchitis, but also in mild to moderate UC not responding to conventional therapy [187].”
• Guidelines for the management of inflammatory bowel disease in adults (2011, background): “7) and some evidence of benefit in maintenance and treatment of ulcerative colitis.(65) 66 Three randomised placebo-controlled studies have shown that E coli Nissle 1917 (Mutaflor ) 200 mg daily is equivalent to”
• Epithelial barriers in homeostasis and disease. (2010, background): “This model may also explain the therapeutic effects of immunosuppressants, immunomodulators (77), and probiotics (149), as well as the potential benefits of barrier preservation (150).”
• Microencapsulation of probiotics for gastrointestinal delivery. (2012, background): “control of release over the small intestine, but not to the farthest regions of the large colon, which would be a target for ulcerative colitis therapy [103].”
• Probiotics and the gut microbiota in intestinal health and disease (2010, background): “In addition, VSLn3 administration is reported to induce remission in patients with ulcerative colitis, as measured by disease activity index”
• Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis (2006, background): “Third, probiotics can prevent the relapse of chronic, relapsing pouchitis and ulcerative colitis, but (with the exception of a single uncontrolled trial in mild-to-moderate active ulcerative colitis patient”